Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease. TYRVAYA is also being evaluated in a Phase II clinical trial for its potential application in treating neurotrophic keratopathy. Oyster Point Pharma was founded in 2015 and was headquartered in Princeton, New Jersey.